Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia
Background: Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest. Aim: To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival an...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Lenguaje: | Spanish / Castilian |
| Publicado: |
Sociedad Médica de Santiago
2018
|
| Materias: | |
| Acceso en línea: | http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000700846 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:scielo:S0034-98872018000700846 |
|---|---|
| record_format |
dspace |
| spelling |
oai:scielo:S0034-988720180007008462018-09-26Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivenciaRamos Peñafiel,ChristianOlarte Carrillo,IrmaCeron Maldonado,RafaelMiranda Peralta,EnriqueRozen Fuller,EttaKassack Ipiña,Juan JulioCenteno Cruz,FedericoCollazo Jaloma,JuanMartínez Tovar,Adolfo Metformin Precursor Cell Lymphoblastic Leukemia-Lymphoma Therapeutics Background: Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest. Aim: To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival and relapse. Material and Methods. We included 123 patients treated with metformin and without metformin. The dose used was 850 mg PO at 8 h intervals. The survival analysis was used by Kaplan-Meier method, the difference between the distinct groups was performed using the log Rank test. Results. The overall survival at a median follow up of 700 days of follow-up was 43%, with a disease-free survival of 47%. Regarding the treatment groups, patients with metformin had a lower rate of relapse compared to the group receiving only chemotherapy (6.5% vs 17.1%, p = 0.006). Conclusions. The addition of metformin to the conventional treatment of ALL was associated with an improvement in survival, this association being independent of the type of biological risk at diagnosis.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.146 n.7 20182018-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000700846es10.4067/s0034-98872018000700846 |
| institution |
Scielo Chile |
| collection |
Scielo Chile |
| language |
Spanish / Castilian |
| topic |
Metformin Precursor Cell Lymphoblastic Leukemia-Lymphoma Therapeutics |
| spellingShingle |
Metformin Precursor Cell Lymphoblastic Leukemia-Lymphoma Therapeutics Ramos Peñafiel,Christian Olarte Carrillo,Irma Ceron Maldonado,Rafael Miranda Peralta,Enrique Rozen Fuller,Etta Kassack Ipiña,Juan Julio Centeno Cruz,Federico Collazo Jaloma,Juan Martínez Tovar,Adolfo Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia |
| description |
Background: Metformin has antineoplastic and cancer protective effects in vitro, sensitizing leukemia cells to chemotherapeutic agents, inducing apoptosis and cell cycle arrest. Aim: To assess the effect of metformin on the induction stage in patients with ALL and its impact on overall survival and relapse. Material and Methods. We included 123 patients treated with metformin and without metformin. The dose used was 850 mg PO at 8 h intervals. The survival analysis was used by Kaplan-Meier method, the difference between the distinct groups was performed using the log Rank test. Results. The overall survival at a median follow up of 700 days of follow-up was 43%, with a disease-free survival of 47%. Regarding the treatment groups, patients with metformin had a lower rate of relapse compared to the group receiving only chemotherapy (6.5% vs 17.1%, p = 0.006). Conclusions. The addition of metformin to the conventional treatment of ALL was associated with an improvement in survival, this association being independent of the type of biological risk at diagnosis. |
| author |
Ramos Peñafiel,Christian Olarte Carrillo,Irma Ceron Maldonado,Rafael Miranda Peralta,Enrique Rozen Fuller,Etta Kassack Ipiña,Juan Julio Centeno Cruz,Federico Collazo Jaloma,Juan Martínez Tovar,Adolfo |
| author_facet |
Ramos Peñafiel,Christian Olarte Carrillo,Irma Ceron Maldonado,Rafael Miranda Peralta,Enrique Rozen Fuller,Etta Kassack Ipiña,Juan Julio Centeno Cruz,Federico Collazo Jaloma,Juan Martínez Tovar,Adolfo |
| author_sort |
Ramos Peñafiel,Christian |
| title |
Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia |
| title_short |
Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia |
| title_full |
Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia |
| title_fullStr |
Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia |
| title_full_unstemmed |
Efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia |
| title_sort |
efecto de la metformina en la etapa de inducción en pacientes con leucemia aguda linfoblástica y su impacto clínico en la supervivencia |
| publisher |
Sociedad Médica de Santiago |
| publishDate |
2018 |
| url |
http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872018000700846 |
| work_keys_str_mv |
AT ramospenafielchristian efectodelametforminaenlaetapadeinduccionenpacientesconleucemiaagudalinfoblasticaysuimpactoclinicoenlasupervivencia AT olartecarrilloirma efectodelametforminaenlaetapadeinduccionenpacientesconleucemiaagudalinfoblasticaysuimpactoclinicoenlasupervivencia AT ceronmaldonadorafael efectodelametforminaenlaetapadeinduccionenpacientesconleucemiaagudalinfoblasticaysuimpactoclinicoenlasupervivencia AT mirandaperaltaenrique efectodelametforminaenlaetapadeinduccionenpacientesconleucemiaagudalinfoblasticaysuimpactoclinicoenlasupervivencia AT rozenfulleretta efectodelametforminaenlaetapadeinduccionenpacientesconleucemiaagudalinfoblasticaysuimpactoclinicoenlasupervivencia AT kassackipinajuanjulio efectodelametforminaenlaetapadeinduccionenpacientesconleucemiaagudalinfoblasticaysuimpactoclinicoenlasupervivencia AT centenocruzfederico efectodelametforminaenlaetapadeinduccionenpacientesconleucemiaagudalinfoblasticaysuimpactoclinicoenlasupervivencia AT collazojalomajuan efectodelametforminaenlaetapadeinduccionenpacientesconleucemiaagudalinfoblasticaysuimpactoclinicoenlasupervivencia AT martineztovaradolfo efectodelametforminaenlaetapadeinduccionenpacientesconleucemiaagudalinfoblasticaysuimpactoclinicoenlasupervivencia |
| _version_ |
1718437013304115200 |